Post-Market Performance Follow-Up — Continuous Obligation
◆ Post-Market Performance Follow-up Report ▼
Post-Market Performance Follow-up (PMPF) Plans and Reports are the IVD equivalents of PMCF Plans and Reports for medical devices. The PMPF Plan defines the proactive approach for collecting and evaluating performance data on an IVD device after it is placed on the market, while the PMPF Report presents the findings of these activities. The PMPF framework addresses specific IVD concerns including ongoing analytical and clinical performance monitoring, surveillance for assay drift, evaluation of new clinical applications, monitoring of the device's performance relative to evolving clinical guidelines, and assessment of performance with new specimen types or patient populations. The PMPF Plan and Report are integral to the IVDR post-market surveillance framework and feed directly into PER updates and PSUR preparation.
Post-Market Performance Follow-up Plan ▼
Post-Market Performance Follow-up (PMPF) Plans and Reports are the IVD equivalents of PMCF Plans and Reports for medical devices. The PMPF Plan defines the proactive approach for collecting and evaluating performance data on an IVD device after it is placed on the market, while the PMPF Report presents the findings of these activities. The PMPF framework addresses specific IVD concerns including ongoing analytical and clinical performance monitoring, surveillance for assay drift, evaluation of new clinical applications, monitoring of the device's performance relative to evolving clinical guidelines, and assessment of performance with new specimen types or patient populations. The PMPF Plan and Report are integral to the IVDR post-market surveillance framework and feed directly into PER updates and PSUR preparation.
Post-Market Performance Studies ▼
Post-Market Performance Follow-up (PMPF) Plans and Reports are the IVD equivalents of PMCF Plans and Reports for medical devices. The PMPF Plan defines the proactive approach for collecting and evaluating performance data on an IVD device after it is placed on the market, while the PMPF Report presents the findings of these activities. The PMPF framework addresses specific IVD concerns including ongoing analytical and clinical performance monitoring, surveillance for assay drift, evaluation of new clinical applications, monitoring of the device's performance relative to evolving clinical guidelines, and assessment of performance with new specimen types or patient populations. The PMPF Plan and Report are integral to the IVDR post-market surveillance framework and feed directly into PER updates and PSUR preparation.
The Periodic Safety Update Report for medical devices is required under the EU MDR for Class IIa, IIb, and III devices. It provides a comprehensive summary and analysis of post-market surveillance data collected over a defined period, including a benefit-risk assessment and an evaluation of whether the device continues to meet the applicable General Safety and Performance Requirements. The PSUR must be prepared at least annually for Class III and implantable devices and at least every two years for Class IIa and IIb devices. It includes analysis of complaint and adverse event data, results of any PMCF activities, relevant literature findings, field safety corrective actions, and manufacturing quality data. The PSUR is submitted through EUDAMED and is reviewed by Notified Bodies and competent authorities as part of their ongoing market surveillance activities.
Trend Reports analyze patterns and trends in post-market data over time for medical devices and IVD products. These reports evaluate complaint data, adverse event reports, product performance metrics, and other quality indicators to identify statistically significant increases in event rates, emerging failure modes, or other trends that may warrant corrective action. Trend analysis is a regulatory requirement under the EU MDR/IVDR and FDA quality system regulations (21 CFR 820.250(b)). The reports must include defined trending methodologies, statistical tools for identifying significant deviations, and threshold criteria for escalation. When trends are identified, the reports document the investigation, root cause analysis, and any corrective or preventive actions taken. Trend reports feed into the broader post-market surveillance system and the periodic safety reporting cycle.
Vigilance Reports are regulatory submissions that notify competent authorities of serious incidents or near-incidents involving medical devices or IVD products on the market. Under the EU MDR/IVDR, manufacturers must report any serious incident that has led or might have led to the death or serious deterioration of health of a patient, user, or other person, as well as any statistically significant increase in the frequency or severity of non-serious incidents. The vigilance reporting system is a cornerstone of post-market safety monitoring. Reports must include detailed descriptions of the incident, the devices involved, patient outcomes, root cause analysis (where available), and any corrective or preventive actions taken or planned. Reporting timelines are strictly defined (ranging from immediate to 15 days depending on severity and urgency) and failure to report is a significant regulatory violation.
Field Safety Corrective Action ▼
A Field Safety Corrective Action is an action taken by a manufacturer of a medical device or IVD to reduce a risk of death or serious deterioration of health associated with a device that is already placed on the market. FSCAs may include device recall, modification, exchange, destruction, retrofit, changes to labeling or instructions for use, or advice on the use of the device. The FSCA documentation includes an assessment of the issue, the rationale for the corrective action, the scope of affected devices (lot numbers, serial numbers, distribution data), the specific actions to be taken, a timeline for implementation, and communication plans. The FSCA must be reported to competent authorities through the vigilance reporting system, and a Field Safety Notice must be issued to inform users and patients of the corrective action.
A Field Safety Notice is a communication sent by a manufacturer to customers, users, and healthcare professionals to inform them of a Field Safety Corrective Action related to a medical device or IVD. It provides details about the safety issue, the affected devices, any recommended actions for users (such as quarantining devices, performing additional testing, or monitoring patients), and contact information for the manufacturer. Field Safety Notices must be clear, concise, and actionable, enabling recipients to quickly understand the issue and take appropriate steps. They must be submitted to competent authorities for review (often before distribution) and are typically distributed via registered mail or other traceable communication channels. The notice must reach all affected users and healthcare professionals and should be written in the appropriate languages for each market.
Complaint Trend Analysis ▼
Complaint Analysis Reports present the systematic evaluation of customer complaints received about a medical product during a defined period. They categorize complaints by type, severity, frequency, and product family; identify the most common complaint themes; evaluate individual complaints that may constitute reportable adverse events or device malfunctions; and assess whether complaint patterns indicate potential design, manufacturing, or labeling issues. These reports are required under quality system regulations and serve as a key input to the post-market surveillance system, risk management process, and CAPA (Corrective and Preventive Action) system. They must demonstrate that each complaint has been appropriately investigated, that reportable events have been identified and submitted to regulatory authorities, and that trends have been analyzed for potential systemic issues requiring corrective action.
Performance Deviation Reports ▼
Performance Deviation Reports document instances where an IVD device's performance deviates from its established specifications or expected behavior. These deviations may include systematic measurement biases, unexpected interference effects, calibration drift, reagent stability issues, or other performance anomalies identified through quality control monitoring, complaint analysis, or post-market surveillance. Each report includes a description of the deviation, the affected products and lots, the root cause investigation, the impact assessment (including any potential impact on clinical decisions made using affected results), and corrective and preventive actions. Performance deviation reports are critical for maintaining the integrity of IVD testing and may trigger Field Safety Corrective Actions, labeling updates, or customer notifications depending on the severity and clinical significance of the deviation.
Updates to Clinical Evaluation Reports, Performance Evaluation Reports, Summaries of Safety and Performance, and Summaries of Safety and Clinical Performance are periodic revisions required to incorporate new clinical evidence, post-market surveillance data, safety information, and changes in the state of the art. These updates ensure that the device's regulatory documentation remains current and reflective of the latest available evidence. Update frequency is defined by the applicable regulatory framework (e.g., at least annually for Class III medical devices under the EU MDR) and must also be triggered by significant new information such as new clinical study results, PMCF findings, safety signals, or changes to the device or its intended use. Each update requires a systematic review of new evidence, reassessment of the benefit-risk profile, and revision of conclusions where warranted. The updated documents must be submitted to Notified Bodies and made available through EUDAMED as required.
Updates to Clinical Evaluation Reports, Performance Evaluation Reports, Summaries of Safety and Performance, and Summaries of Safety and Clinical Performance are periodic revisions required to incorporate new clinical evidence, post-market surveillance data, safety information, and changes in the state of the art. These updates ensure that the device's regulatory documentation remains current and reflective of the latest available evidence. Update frequency is defined by the applicable regulatory framework (e.g., at least annually for Class III medical devices under the EU MDR) and must also be triggered by significant new information such as new clinical study results, PMCF findings, safety signals, or changes to the device or its intended use. Each update requires a systematic review of new evidence, reassessment of the benefit-risk profile, and revision of conclusions where warranted. The updated documents must be submitted to Notified Bodies and made available through EUDAMED as required.
